We conducted a Doc call with Dr. Sanjay Mathew M.D., Vice Chair of Research and Professor of Psychiatry at Baylor College of Medicine.
High level, Dr. Mathew was enthusiastic about Auvelity based on:
Rapid onset of action within a week
Good safety with no REMS or DEA scheduling
Overall psychiatrist familiarity with bupropion (Wellbutrin) and comfort with dealing with its DDI related issues
Dr. Mathew added that, in an ideal world, where there are no payor restrictions, he would probably use Auvelity as first-line therapy in the vast majority of his MDD patients, primarily due to its rapid antidepressant effects. However, Dr. Mathew anticipates payor pushback, pending pricing of Auvelity and given cheap generics, though they may not be as effective.
While Auvelity label comes with numerous warnings, mostly related to DDI, Dr. Mathew did not see anything particularly concerning in terms of safety. He did not find anything particularly onerous that would act as a hindrance for prescribers. In fact, heviewed the lack of REMS requirement and DEA scheduling as possibly having a commercial edge against some of the other drugs in development that are likely to have DEA scheduling, at least at first, if approved
Also, while some investors have historically pointed out that AXS-05 (Auvelity) is a combination of DM and BUP, which can be compounded, Dr. Mathews mentioned that "astronomically small proportion" of psychiatrists would send patients to compounding pharmacy due to associated liabilities and availability of an FDA approved drug
We spoke with AXSM management today, who expressed commercial readiness of Auvelity, come 4Q22, based on highly differentiated drug profile. Management reiterated that Auvelity satisfied two key conditions necessary to qualify as rapid-acting antidepressant, as defined per FDA draft guidance on MDD drug products (HERE). The draft guidance defines rapid-acting antidepressant as those that demonstrate efficacy within a week with durable effects. Management reiterated that Auvelity has fullfilled both prespecified conditions in a prospective trial.
Net-net we came away incrementally positive on the commercial outlook for Auvelity and see significant upside to current share price of AXSM. Reiterate BUY
Recent AXSM News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 11:05:39 AM
- Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine • GlobeNewswire Inc. • 09/04/2024 11:00:00 AM
- Axsome Therapeutics to Participate in Investor Conferences in September • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 11:05:55 AM
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. • GlobeNewswire Inc. • 08/21/2024 11:00:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:27:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 09:07:28 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/05/2024 08:36:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:05:45 AM
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/05/2024 11:00:00 AM
- U.S. Index Futures and Oil Prices Plunge on Recession Concerns • IH Market News • 08/05/2024 09:46:20 AM
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:31:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:38:42 AM
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories • GlobeNewswire Inc. • 06/05/2024 11:35:00 AM
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:12:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:11:32 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:24:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:23:38 PM
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM